Microbial contamination of hematopoietic progenitor cell products: clinical outcome

We reviewed the results of routine microbiological assays of 3078 infused hematopoietic progenitor cell (HPC) products for autologous and allogeneic transplantation between January 2001 and December 2005. Thirty-seven (1.2%) contaminated products were found. All patients receiving contaminated infus...

Full description

Saved in:
Bibliographic Details
Published inBone marrow transplantation (Basingstoke) Vol. 40; no. 3; p. 365
Main Authors Patah, P A, Parmar, S, McMannis, J, Sadeghi, T, Karandish, S, Rondon, G, Tarrand, J, Champlin, R, de Lima M, Shpall, E J
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group 01.08.2007
Subjects
Clinical outcomes
Stem cell transplantation
Online AccessGet full text

Cover

More Information
Summary:We reviewed the results of routine microbiological assays of 3078 infused hematopoietic progenitor cell (HPC) products for autologous and allogeneic transplantation between January 2001 and December 2005. Thirty-seven (1.2%) contaminated products were found. All patients receiving contaminated infusions received empirical antibiotic prophylaxis according to the assay result. None of these patients developed a positive blood culture with the same agent, developed infections that could be attributable to the contaminated product or experienced any clinical sequelae. Coagulase-negative Staphylococcus was found in 32 (86.5%) products. Admission lengths and time to engraftment were within the expected time frame for autologous and allogeneic transplants. Microbial contamination of HPC products occurs at a low frequency; prophylactic use of antibiotics based on the microbiological assay appears to be effective in preventing clinical complications.
ISSN:0268-3369
1476-5365